-
1 Comment
Lionco Pharmaceutical Group Co., Ltd is currently in a long term downtrend where the price is trading 29.2% below its 200 day moving average.
From a valuation standpoint, the stock is 46.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.2.
Lionco Pharmaceutical Group Co., Ltd's total revenue sank by 20.9% to $296M since the same quarter in the previous year.
Its net income has increased by 84.6% to $76M since the same quarter in the previous year.
Finally, its free cash flow fell by 48.0% to $23M since the same quarter in the previous year.
Based on the above factors, Lionco Pharmaceutical Group Co., Ltd gets an overall score of 2/5.
| Exchange | SHG |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE1000022R8 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | 3B |
|---|---|
| PE Ratio | None |
| Target Price | 31.85 |
| Beta | 0.6 |
| Dividend Yield | None |
Lionco Pharmaceutical Group Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in China. The company offers nutrition, antimicrobial, antiviral, digestion, cardiovascular, detoxification, anti-tumor, and other products. Lionco Pharmaceutical Group Co., Ltd. was founded in 2003 and is based in Shannan, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 603669.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
